Ozempic vs Wegovy
Ozempic and Wegovy are both semaglutide — the same molecule, made by the same company (Novo Nordisk). The difference is the approved indication and dosing. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. This is one of the most searched peptide comparisons, and the confusion is understandable.
Ozempic and Wegovy are the exact same drug — semaglutide, made by Novo Nordisk. The difference is entirely regulatory: Ozempic is branded and approved for type 2 diabetes; Wegovy is branded and approved for weight management. Wegovy goes to higher doses (up to 7.2mg), which is why it produces more weight loss. Many patients get Ozempic off-label for weight loss when insurance won't cover Wegovy.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
| Category | Semaglutide | Semaglutide |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide (identical molecule) |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-Approved For | Type 2 diabetes (as adjunct to diet and exercise) | Chronic weight management (BMI ≥30, or ≥27 with comorbidity) |
| Maximum Dose | 2.0 mg once weekly | 7.2 mg once weekly (approved Jan 2026 for BMI ≥30; administered as 3× 2.4mg injections) |
| Standard Maintenance Dose | 0.5mg, 1.0mg, or 2.0mg weekly (based on glycemic response) | 2.4 mg once weekly (most patients); 7.2mg available after ≥4 weeks at 2.4mg |
| Dose Escalation | 0.25mg → 0.5mg → 1.0mg → 2.0mg over ~8 weeks | 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg over ~17 weeks |
| Key Trial Program | SUSTAIN (7 Phase III trials in T2DM) | STEP (4+ Phase III trials in obesity) |
| Weight Loss (Trial Data) | ~5-7% body weight (at diabetes doses) | ~15% body weight at 2.4mg (STEP 1, 68 weeks) |
| Cardiovascular Data | SUSTAIN-6: reduced MACE in T2DM | SELECT: 20% MACE reduction in obesity without diabetes |
| Oral Form Available | Yes — Rybelsus (oral semaglutide 7mg/14mg) | Yes — oral Wegovy 25mg (approved Jan 2026) |
| Insurance Coverage | Broader — most insurance covers for T2DM | More limited — many insurers exclude weight management |
| Cost Without Insurance | ~$900–$1,100/month | ~$1,300–$1,400/month |
| Can One Substitute for the Other? | Off-label use for weight loss is common but not FDA-approved | Not indicated for diabetes unless patient also qualifies |
In depth
Same molecule, different label
Ozempic and Wegovy are chemically identical — both are semaglutide, manufactured by Novo Nordisk. The molecule in your syringe is the same molecule regardless of which brand name is on the pen. What differs is the FDA approval: Ozempic is approved for type 2 diabetes management, Wegovy is approved for chronic weight management in adults with BMI ≥30 (or ≥27 with a weight-related comorbidity). When a drugmaker seeks approval for the same molecule in two indications, they typically file separate applications and brand them separately to streamline marketing, insurance coverage, and dosing regimens. This is a common pharmaceutical pattern, not a conspiracy — Zepbound and Mounjaro (tirzepatide) follow exactly the same playbook.
Dosing is the real practical difference
Because the approved indications differ, the dosing caps differ. Ozempic tops out at 2.0 mg weekly. Wegovy's standard maintenance is 2.4 mg weekly — already higher than Ozempic's ceiling — and since January 2026, a 7.2 mg weekly dose is approved for patients with BMI ≥30 who need additional weight loss after at least 4 weeks at 2.4 mg (administered as three 2.4 mg injections on the same day). The dose escalation schedules also differ: Ozempic titrates over ~8 weeks, Wegovy over ~17 weeks, with the slower Wegovy titration reflecting the tolerability challenges at higher doses.
Weight loss expectations reflect the dosing
At Ozempic's diabetes doses, weight loss is modest — roughly 5–7% body weight. That's real but not transformative. Wegovy at 2.4 mg delivers ~15% body weight loss in the STEP trials. The new 7.2 mg approval promises additional weight loss for patients who need it, though long-term real-world data on the higher dose is just starting to accumulate. If weight management is the primary goal, Wegovy's higher dosing ceiling and purpose-built weight-loss indication make it the better-evidenced choice.
Cardiovascular evidence
Both versions have cardiovascular outcome trial evidence, but for different populations. Ozempic's SUSTAIN-6 showed MACE reduction in type 2 diabetics. Wegovy's SELECT trial — the more landmark result — showed a 20% MACE reduction in obesity without diabetes, extending GLP-1 cardiovascular benefit to a population that the diabetes trials didn't cover. That's why Wegovy is now prescribed specifically for cardiovascular risk reduction in eligible patients, not just weight.
Insurance and the off-label reality
Because insurance typically covers Ozempic for diabetes but often excludes Wegovy for weight management, many patients end up being prescribed Ozempic off-label for weight loss. This is a cost-driven workaround, not a clinical recommendation — and because Ozempic is capped at 2.0 mg, patients using it off-label often plateau at more modest weight loss than a Wegovy dose titration would achieve. Compounded semaglutide — available during the brand supply constraints and still in some pharmacy channels — offers a third path at equivalent doses if cost is the primary barrier, though the compounding pharmacy landscape has tightened since the FDA declared the shortage resolved.
Bottom line
If you have type 2 diabetes, Ozempic is the appropriate indication and the one insurance is likely to cover. If your primary goal is weight management and you qualify for Wegovy, it has the stronger evidence base (SELECT, STEP program) and the higher dosing ceiling. If insurance is the barrier, discussing off-label Ozempic or compounded semaglutide with your clinician is reasonable, recognizing the dose ceiling differences. The molecule is the same — the decision is about which regulatory-and-dosing wrapper best fits your medical situation and coverage.
These peptides are often used together. See our stack profiles for combination details.